Study Details

Back to Search Results

A study to explore efficacy and safety of ASP015K in subjects with moderate to severe psoriasis

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01096862

Astellas Study ID

The unique identification code given by the study sponsor.

015K-CL-PS01

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Psoriasis

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Mar 2010 - Jul 2011

Masking

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Enrollment number

124

A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects with Moderate to Severe Plaque Psoriasis

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A study to explore efficacy and safety of ASP015K in subjects with moderate to severe psoriasis? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Oregon Medical Research Center

Portland, United States, 97223

FXM Research, Corp.

Miami, United States, 33175

Palmetto Clinical Trial Services

Greenville, United States, 29607

Virginia Clinical Research

Norfolk, United States, 23507

Total Skin & Beauty Dermatology Center

Birmingham, United States, 35205

J & S Studies

College Station, United States, 77845

Derm Research, PLLC

Louisville, United States, 40217

Renstar Medical Research

Ocala, United States, 34471

Therapeutics Clinical Research

San Diego, United States, 92123

Madison Skin & Research, Inc

Madison, United States, 53719

Rivergate Dermatology

Goodlettsville, United States, 37072

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo